AACR Meeting Highlights

Nivolumab a New Standard-of-Care Option for Recurrent/Metastatic Head and Neck Cancers

Nivolumab a New Standard-of-Care Option for Recurrent/Metastatic Head and Neck Cancers

May 2016, Vol 7, No 4 - AACR Meeting Highlights

Anti–PD-1 treatment with the PD-1 inhibitor nivolumab (Opdivo) significantly improved survival in patients with head and neck squamous-cell carcinoma that progressed after platinum-based therapy, according to data from a phase 3 clinical trial known as CheckMate-141. Based on these data, [ Read More ]

New Hope for Patients with Advanced Lung Cancer?

Phoebe Starr

May 2015, Vol 6, No 4 - AACR Meeting Highlights

Philadelphia, PA—Immunotherapy with pembrolizumab (Keytruda) was safe and effective in the treatment of patients with previously treated as well as treatment-naïve patients with advanced non–small-cell lung cancer (NSCLC), according to results of the KEYNOTE-001 trial, said Edward B. Garon, MD, Assistant Professor of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Santa Monica, who presented these data at the 2015 American Association for Cancer Research (AACR) meeting. [ Read More ]

Olaparib-Carboplatin Combination Shows Promise for Patients with Ovarian or Triple-Negative Breast Cancer

Dana Taylor

May 2015, Vol 6, No 4 - AACR Meeting Highlights

Philadelphia, PA—The use of the poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib (Lynparza), plus carboplatin chemotherapy shows promising activity in patients with recurrent breast or ovarian cancer; furthermore, the order of administration of these therapies did not affect the occurrence of side effects, according to new data from a phase 1 clinical trial presented at the 2015 American Association for Cancer Research (AACR) meeting. [ Read More ]

Metformin May Not Improve Survival in Patients with Pancreatic Cancer

Christine Erickson

May 2015, Vol 6, No 4 - AACR Meeting Highlights

Philadelphia, PA—Several retrospective studies have shown that metformin is associated with longer survival in patients with cancer, including pancreatic cancer. However, in a new study led by Roongruedee Chaiteerakij, MD, PhD, Division of Gastroenterology and Hepatology, Mayo Clinic Cancer Center, Rochester, MN, metformin did not improve survival for patients with pancreatic ductal adenocarcinoma (PDAC). The results were presented at the 2015 American Association for Cancer Research meeting. [ Read More ]

Projections for 2030: Increase in ER-Positive, Decrease in ER-Negative Breast Cancer

Phoebe Starr

May 2015, Vol 6, No 4 - AACR Meeting Highlights

Philadelphia, PA—Over the next 15 years, up to a 50% increase is projected in the number of breast cancer cases, according to a study from the National Cancer Institute (NCI). The incidence of estrogen receptor (ER)-positive breast cancers, diagnosed mostly by mammography, is projected to increase, whereas cases of ER-negative cancers, the more-difficult-to-treat cancers, are projected to decrease. ER-positive in situ cancers are expected to increase by approximately 50% and ER-negative cancers are expected to decrease by approximately 50% by 2030. [ Read More ]

Two Immunotherapies Are Better Than One in Advanced Melanoma

Phoebe Starr

May 2015, Vol 6, No 4 - AACR Meeting Highlights

Philadelphia, PA—Combination immunotherapy with ipilimumab (Yervoy) plus nivolumab (Opdivo) was superior to ipilimumab monotherapy in previously untreated patients with advanced melanoma in a phase 2 randomized clinical trial, according to lead investigator F. Stephen Hodi, MD, Director of the Melanoma Center, Dana-Farber Cancer Institute, Boston, MA, who presented the study at the 2015 American Association for Cancer Research (AACR) annual meeting. [ Read More ]

Pembrolizumab Scores Big Over Ipilimumab in Advanced Melanoma

Phoebe Starr

May 2015, Vol 6, No 4 - AACR Meeting Highlights

Philadelphia, PA—As new immunotherapies become available for the treatment of melanoma and other cancers, head-to-head trials of these agents shed more light on how best to use them. In the phase 3 KEYNOTE-006 trial, pembrolizumab (Keytruda) outperformed ipilimumab (Yervoy)—a current standard of care—as upfront treatment for patients with unresectable advanced melanoma. The data were presented at the 2015 American Association for Cancer Research annual meeting. [ Read More ]